Recent advances in therapy for gastrointestinal stromal tumors

Current Oncology Reports

Volumn 9, Issue 3, 2007, Pages 165-169

  Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMATINIB; PHOSPHOTRANSFERASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

CANCER RISK; CANCER SIZE; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INCIDENTAL FINDING; INTERSTITIAL CELL OF CAJAL; METASTASIS POTENTIAL; OUTCOMES RESEARCH; REVIEW; RISK ASSESSMENT; SARCOMA; STANDARDIZATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; NEOPLASM METASTASIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 34248398437     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0017-0     Document Type: Review

References (27)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005, 103:821-829.
3. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465.
4. Huizinga JD, Thuneberg L, Kluppel M, et al.: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373:347-349.
5. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
6. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromai tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
7. Ng EH, Pollock RE, Munsell MF, et al.: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68-77.
8. Ng EH, Pollock RE, Romsdahl MM: Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992, 69:1334-1341.
9. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466-477.
10. DeMatteo RP, Antonescu CR, Chadaram V, et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005, 23:9009.
11. American College of Surgeons: Z9001 Synopsis, vol. 2006. Synopsis of Z9001 adjuvant GIST study in PDF format; 2006. http://clinicaltrials.gov/ct/show/NCT00041197. Accessed 3/1/07.
12. Eilber FC, Rosen G, Forscher C, et al.: Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999, 6:645-650.
13. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
14. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
15. Corless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005. 23:5357-5364.
16. Shankar S, vanSonnenberg E, Desai J, et al.: Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005, 235:892-898.
17. Antonescu CR, Besmer P, Guo T, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11:4182-4190.
18. Heinrich MC, Maki RG, Corless CL, et al.: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 2006, 24:9502.
19. Casali PG, Garrett CR, Blackstein ME, et al.: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006, 24:9513.
20. Heinrich MC, Maki RG, Corless CL, et al.: Correlation of KIT and PDGFRA Mutation Status with Sunitinib Malate (SU11248) Activity in Imatinib-resistant GIST. Presented at AACR Molecular Diagnostics in Cancer Therapeutic Development meeting. Chicago, IL; 2006.
21. Blay JY, Bonvalot S, Casali P, et al.: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578.
22. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al.: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12:1743-1749.
23. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6:249-251.
24. Fabian MA, Biggs WH III, Treiber DK, et al.: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336.
25. van Oosterom AT, Dumez H, Desai J, et al.: Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol 2004, 22:3002.
26. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
27. Nakatani H, Kobayashi M, Jin T, et al.: STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 2005, 96:116-119.